ESSA PHARMA INC's ticker is EPIX and the CUSIP is 29668H708. A total of 38 filers reported holding ESSA PHARMA INC in Q1 2023. The put-call ratio across all filers is 1.56 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,463,288 | +15.6% | 473,556 | +1.0% | 0.00% | 0.0% |
| Q2 2023 | $1,266,305 | +101611.2% | 469,002 | +11.9% | 0.00% | 0.0% |
| Q1 2023 | $1,245 | +183.0% | 419,067 | +140.2% | 0.00% | – |
| Q4 2022 | $440 | -99.9% | 174,475 | -57.1% | 0.00% | – |
| Q3 2022 | $740,000 | -28.1% | 406,761 | +24.5% | 0.00% | -100.0% |
| Q2 2022 | $1,029,000 | -17.6% | 326,730 | +61.7% | 0.00% | 0.0% |
| Q1 2022 | $1,249,000 | -35.1% | 202,047 | +49.1% | 0.00% | 0.0% |
| Q4 2021 | $1,925,000 | -3.2% | 135,550 | -45.5% | 0.00% | 0.0% |
| Q3 2021 | $1,989,000 | +211.8% | 248,687 | +1014.3% | 0.00% | – |
| Q2 2021 | $638,000 | -45.0% | 22,318 | -44.2% | 0.00% | -100.0% |
| Q1 2021 | $1,161,000 | +138.9% | 39,969 | -2.0% | 0.00% | – |
| Q4 2020 | $486,000 | +11.7% | 40,769 | -35.3% | 0.00% | -100.0% |
| Q3 2020 | $435,000 | – | 62,976 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soleus Capital Management, L.P. | 4,223,799 | $26,103,000 | 3.37% |
| MPM BioImpact LLC | 660,892 | $4,084,000 | 1.10% |
| BVF INC/IL | 3,695,629 | $22,839,000 | 0.91% |
| Omega Fund Management, LLC | 328,196 | $2,028,000 | 0.42% |
| Eventide Asset Management | 4,170,259 | $25,772,000 | 0.40% |
| Frazier Life Sciences Management, L.P. | 692,910 | $4,282,000 | 0.36% |
| Bellevue Group AG | 5,034,814 | $31,115,000 | 0.36% |
| RTW INVESTMENTS, LP | 2,637,192 | $16,298,000 | 0.34% |
| Avidity Partners Management LP | 2,460,000 | $15,203,000 | 0.32% |
| Rhenman & Partners Asset Management AB | 410,923 | $2,540,000 | 0.25% |